Biological therapy in Crohn's disease.
The discovery of the central role of tumour necrosis factor-alpha in Crohn's disease and the subsequent introduction of infliximab into routine clinical practice has transformed the treatment of refractory disease. Advances in understanding of the immunopathological basis of Crohn's disease are leading to the development of new biological therapies which are likely to play an increasing role in future.
Gordon
J N
JN
Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD.
MacDonald
T T
TT
D001691:Biological Therapy / Q000379:methods*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D016201:Receptors, Lymphocyte Homing / Q000037:antagonists & inhibitors; D018417:Th1 Cells / Q000276:immunology
D016207:Cytokines; D016201:Receptors, Lymphocyte Homing